Isozaki T, Kimura M, Ikegaya N, Arai T, Fujigaki Y, Hishida A, Kaneko E
Department of Medicine, Hamamatsu University School of Medicine.
Clin Investig. 1992 Nov;70(11):1036-42. doi: 10.1007/BF00180315.
Two cases of nephrotic syndrome during bucillamine treatment were encountered in 1989 in our hospital; both patients had suffered from rheumatoid arthritis for 2 years. They had received 200 mg bucillamine orally per day for 3-4 months before the onset of the nephrotic syndrome. Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. Bucillamine is a new therapeutic agent for rheumatoid arthritis developed in 1982 in Japan. Since 1985, 14 cases of nephrotic syndrome, including the two cases reported here have been reported. We review these cases and discuss the pathogenesis.
1989年我院遇到2例服用青霉胺治疗期间出现肾病综合征的病例；这2例患者均患类风湿关节炎2年。在肾病综合征发病前，他们每天口服200毫克青霉胺，持续3 - 4个月。停用青霉胺后，肾病综合征在1年内完全缓解。青霉胺是1982年在日本研发的一种治疗类风湿关节炎的新药。自1985年以来，包括本文报道的2例在内，共报告了14例肾病综合征病例。我们回顾这些病例并讨论其发病机制。
